GET DAILY SIGNALSWhy Is InflaRx N.V. (IFRX) Stock Down -11.81% Today?
Key Takeaways
- IFRX shares fell roughly 11.81% intraday to about $1.195, down from the prior session's close of $1.355.
- The decline extends a multi-day slide triggered by a Capital Markets Day update that pushed key izicopan data readouts out to 2028.
- A broad risk-off tape across technology and biotech names compounded the selling pressure in this high-beta, thinly traded stock.
- Elevated short interest and penny-stock volatility are amplifying the downside move.
- Traders are watching upcoming investor conferences and any regulatory feedback on the company's ANCA-associated vasculitis program.
- For additional detail on valuation, financials, and expectations, explore Price Targets, Earnings, and Forecast pages for this ticker.
- For AI-driven trading ideas across the market, explore Trending AI Robots.
Opening Summary
InflaRx N.V. (IFRX), a clinical-stage biopharmaceutical company based in Jena, Germany, that develops anti-inflammatory therapies targeting the complement system, saw its stock fall sharply in Thursday's session. Shares traded down approximately 11.81% to around $1.195, compared with a prior close of $1.355. The move marks the fourth consecutive session of selling and follows the company's November 3 third-quarter earnings release and virtual Capital Markets Day, where management detailed the development path for its lead oral C5a receptor inhibitor, izicopan, in ANCA-associated vasculitis (AAV).
Capital Markets Day and Q3 Update: A Long Timeline to Data
The most immediate driver behind the sell-off in IFRX is investor disappointment over the extended development timeline for izicopan. At its Capital Markets Day, InflaRx outlined plans to begin two Phase 2 trials in AAV, with site initiation expected in early 2027 and the first data readouts not anticipated until 2028. For a speculative clinical-stage biotech, the absence of near-term catalysts for roughly two years has prompted some investors to reduce positions, even though the company reported a narrower-than-expected third-quarter loss of €0.02 per share and reiterated a cash runway extending through 2029.
Management also provided a peak sales estimate of $1.5 billion to $2.0 billion for izicopan in AAV, a company projection that carries substantial uncertainty given the early stage of development. While the underlying safety and Phase 2a data for izicopan remain supportive, the market reaction reflects a "show-me" posture, with traders unwilling to hold through a prolonged data-free period.
Broad Market Risk-Off and Sector Pressure
The decline in IFRX is also being amplified by a risk-off environment across equity markets. Broader technology and growth indices traded sharply lower during the session, with volatility gauges spiking as investors rotated away from high-risk, speculative assets. Biotechnology stocks, which typically carry elevated sensitivity to both interest rates and risk appetite, have been among the hardest hit. For a pre-revenue, high-beta name like IFRX, this macro backdrop has intensified the selling pressure already triggered by the company-specific news.
Positioning, Volatility, and Technical Factors
Several structural factors are magnifying the move. IFRX trades well below $5 per share, placing it firmly in penny-stock territory, where liquidity can thin quickly and daily swings are pronounced. The stock carries a five-year beta above 2, meaning it moves roughly twice as much as the broader market. Short interest stood at about 12.7 million shares as of mid-October, representing roughly 9.4% of shares outstanding, which can add to downside momentum during risk-off periods. The shares have also fallen below their 50-day and 200-day moving averages, reinforcing negative technical sentiment.
Market Context and Trading Activity
Trading volume has been well above normal during the recent decline, with turnover on the November 3 session running several multiples of the stock's three-month average of roughly 850,000 shares. The sustained elevated volume suggests genuine distribution rather than a single isolated order, as holders react to the re-priced timeline and the broader market weakness. The move has diverged from the stock's earlier-year rally and now reflects a decisive repricing of near-term catalysts.
What Comes Next for IFRX
Looking ahead, investors in IFRX will monitor several scheduled events, including a fireside chat at the Guggenheim healthcare conference on November 10 and the Jefferies conference in London later in November. Regulatory engagement with the FDA and European Medicines Agency on the AAV development path, along with any update on Phase 2 trial design and endpoints, will be closely watched. Key risks include clinical failure, further regulatory delays, the extended timeline to data, and the possibility of future dilutive financings despite the company's current cash position. While the company's balance sheet provides a multi-year runway, the absence of near-term binary catalysts leaves the stock exposed to macro-driven volatility.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers, but only the strongest performers under current market conditions are highlighted in the curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of approaches for navigating volatile names like IFRX. Explore the page to see which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IFRX's RSI Indicator ascending out of oversold territory
The RSI Indicator for IFRX moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 27 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for IFRX just turned positive on October 21, 2026. Looking at past instances where IFRX's MACD turned positive, the stock continued to rise in 42 of 48 cases over the following month. The odds of a continued upward trend are 88%.
Following a +9.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where IFRX advanced for three days, in 184 of 228 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
IFRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IFRX as a result. In 87 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IFRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for IFRX entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.366) is normal, around the industry mean (2.788). P/E Ratio (-2.710) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. IFRX's P/S Ratio (3333.333) is slightly higher than the industry average of (440.869).
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. IFRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IFRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biopharmaceutical products
Industry Biotechnology
Advertisement